Jose B. Cibelli
Michigan State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jose B. Cibelli.
PLOS ONE | 2010
Steven T. Suhr; Eun Ah Chang; Jonathan Tjong; Nathan Alcasid; Guy A. Perkins; Marcelo D. Goissis; Mark H. Ellisman; Gloria I. Perez; Jose B. Cibelli
Background As stem cells of the early embryo mature and differentiate into all tissues, the mitochondrial complement undergoes dramatic functional improvement. Mitochondrial activity is low to minimize generation of DNA-damaging reactive oxygen species during pre-implantation development and increases following implantation and differentiation to meet higher metabolic demands. It has recently been reported that when the stem cell type known as induced pluripotent stem cells (IPSCs) are re-differentiated for several weeks in vitro, the mitochondrial complement progressively re-acquires properties approximating input fibroblasts, suggesting that despite the observation that IPSC conversion “resets” some parameters of cellular aging such as telomere length, it may have little impact on other age-affected cellular systems such as mitochondria in IPSC-derived cells. Methodology/Principal Findings We have examined the properties of mitochondria in two fibroblast lines, corresponding IPSCs, and fibroblasts re-derived from IPSCs using biochemical methods and electron microscopy, and found a dramatic improvement in the quality and function of the mitochondrial complement of the re-derived fibroblasts compared to input fibroblasts. This observation likely stems from two aspects of our experimental design: 1) that the input cell lines used were of advanced cellular age and contained an inefficient mitochondrial complement, and 2) the re-derived fibroblasts were produced using an extensive differentiation regimen that may more closely mimic the degree of growth and maturation found in a developing mammal. Conclusions/Significance These results — coupled with earlier data from our laboratory — suggest that IPSC conversion not only resets the “biological clock”, but can also rejuvenate the energetic capacity of derived cells.
PLOS ONE | 2009
Steven T. Suhr; Eun Ah Chang; Ramón María Alvargonzález Rodríguez; Kai Wang; Pablo J. Ross; Zeki Beyhan; Shashanka Murthy; Jose B. Cibelli
Background Human induced pluripotent stem cells (IPSCs) have enormous potential in the development of cellular models of human disease and represent a potential source of autologous cells and tissues for therapeutic use. A question remains as to the biological age of IPSCs, in particular when isolated from older subjects. Studies of cloned animals indicate that somatic cells reprogrammed to pluripotency variably display telomere elongation, a common indicator of cell “rejuvenation.” Methodology/Principal Findings We examined telomere lengths in human skin fibroblasts isolated from younger and older subjects, fibroblasts converted to IPSCs, and IPSCs redifferentiated through teratoma formation and explant culture. In IPSCs analyzed at passage five (P5), telomeres were significantly elongated in 6/7 lines by >40% and approximated telomere lengths in human embryonic stem cells (hESCs). In cell lines derived from three IPSC-teratoma explants cultured to P5, two displayed telomeres shortened to lengths similar to input fibroblasts while the third line retained elongated telomeres. Conclusions/Significance While these results reveal some heterogeneity in the reprogramming process with respect to telomere length, human somatic cells reprogrammed to pluripotency generally displayed elongated telomeres that suggest that they will not age prematurely when isolated from subjects of essentially any age.
PLOS ONE | 2010
Beatriz Suarez-Alvarez; Ramón María Alvargonzález Rodríguez; Vincenzo Calvanese; Miguel Angel Blanco-Gelaz; Steve T. Suhr; Francisco B. Ortega; Jesus Otero; Jose B. Cibelli; Harry Moore; Mario F. Fraga; Carlos López-Larrea
Background Human embryonic stem cells (hESCs) are an attractive resource for new therapeutic approaches that involve tissue regeneration. hESCs have exhibited low immunogenicity due to low levels of Mayor Histocompatibility Complex (MHC) class-I and absence of MHC class-II expression. Nevertheless, the mechanisms regulating MHC expression in hESCs had not been explored. Methodology/Principal Findings We analyzed the expression levels of classical and non-classical MHC class-I, MHC class-II molecules, antigen-processing machinery (APM) components and NKG2D ligands (NKG2D-L) in hESCs, induced pluripotent stem cells (iPSCs) and NTera2 (NT2) teratocarcinoma cell line. Epigenetic mechanisms involved in the regulation of these genes were investigated by bisulfite sequencing and chromatin immunoprecipitation (ChIP) assays. We showed that low levels of MHC class-I molecules were associated with absent or reduced expression of the transporter associated with antigen processing 1 (TAP-1) and tapasin (TPN) components in hESCs and iPSCs, which are involved in the transport and load of peptides. Furthermore, lack of β2-microglobulin (β2m) light chain in these cells limited the expression of MHC class I trimeric molecule on the cell surface. NKG2D ligands (MICA, MICB) were observed in all pluripotent stem cells lines. Epigenetic analysis showed that H3K9me3 repressed the TPN gene in undifferentiated cells whilst HLA-B and β2m acquired the H3K4me3 modification during the differentiation to embryoid bodies (EBs). Absence of HLA-DR and HLA-G expression was regulated by DNA methylation. Conclusions/Significance Our data provide fundamental evidence for the epigenetic control of MHC in hESCs and iPSCs. Reduced MHC class I and class II expression in hESCs and iPSCs can limit their recognition by the immune response against these cells. The knowledge of these mechanisms will further allow the development of strategies to induce tolerance and improve stem cell allograft acceptance.
Science | 2009
R. M. Roberts; George W. Smith; Fuller W. Bazer; Jose B. Cibelli; G.E. Seidel; Dale E. Bauman; Lawrence P. Reynolds; James J. Ireland
Inadequate funding threatens vital agricultural and biomedical research with farm animals. The annual economic value of livestock and poultry sales in the United States currently exceeds
Stem Cells and Development | 2011
Jiesi Luo; Steven T. Suhr; Eun Ah Chang; Kai Wang; Pablo J. Ross; Laura L. Nelson; Patrick J. Venta; Jason G. Knott; Jose B. Cibelli
132 billion (1), yet only about 0.04% (
Proceedings of the National Academy of Sciences of the United States of America | 2012
Sebastian Canovas; Jose B. Cibelli; Pablo J. Ross
32.15 million) (2) of the
Cloning and Stem Cells | 2003
Sayaka Wakayama; Jose B. Cibelli; Teruhiko Wakayama
88 billion Department of Agriculture (USDA) budget in fiscal year 2007 (3) was allocated to its competitive grants program for research that directly involves agriculturally important domestic animals. By contrast, the Department of Health and Human Services (DHHS) apportioned 4.1% (
Experimental Neurology | 2013
Samuel E. Nutt; Eun Ah Chang; Steven T. Suhr; Laura O. Schlosser; Sarah E. Mondello; Chet T. Moritz; Jose B. Cibelli; Philip J. Horner
29.5 billion) of its
Theriogenology | 2012
N. Rodriguez-Osorio; R. Urrego; Jose B. Cibelli; Kenneth J. Eilertsen; E. Memili
716 billion budget in fiscal year 2008 to the National Institutes of Health (NIH) of which ∼80% supported extramural research (4). Whether this direct comparison between USDA and DHHS is appropriate may be debatable; still, it clearly illustrates the huge disparity in total budget available for research grants focused on animal agriculture, about 1/918th that for human health. The private sector does invest in agricultural research and development, but, understandably, such funds are highly focused on commercial interests and not on basic research of the kind we discuss.
Science | 2014
Elena Gonzalez-Muñoz; Yohanna Arboleda-Estudillo; Hasan H. Otu; Jose B. Cibelli
For more than thirty years, the dog has been used as a model for human diseases. Despite efforts made to develop canine embryonic stem cells, success has been elusive. Here, we report the generation of canine induced pluripotent stem cells (ciPSCs) from canine adult fibroblasts, which we accomplished by introducing human OCT4, SOX2, c-MYC, and KLF4. The ciPSCs expressed critical pluripotency markers and showed evidence of silencing the viral vectors and normal karyotypes. Microsatellite analysis indicated that the ciPSCs showed the same profile as the donor fibroblasts but differed from cells taken from other dogs. Under culture conditions favoring differentiation, the ciPSCs could form cell derivatives from the ectoderm, mesoderm, and endoderm. Further, the ciPSCs required leukemia inhibitory factor and basic fibroblast growth factor to survive, proliferate, and maintain pluripotency. Our results demonstrate an efficient method for deriving canine pluripotent stem cells, providing a powerful platform for the development of new models for regenerative medicine, as well as for the study of the onset, progression, and treatment of human and canine genetic diseases.